サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1364782

エピジェネティクス医薬品・診断技術の世界市場の予測（～2032年）

Epigenetics Drugs and Diagnostic Technologies Market Research Report Forecast to 2032

出版日
ページ情報
英文 128 Pages
納期
お問合せ
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
エピジェネティクス医薬品・診断技術の世界市場の予測（～2032年）
出版日: 2023年10月12日
発行: Market Research Future
ページ情報: 英文 128 Pages
納期: お問合せ
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のエピジェネティクス医薬品・診断技術の市場規模は、調査期間中にCAGRで21.90%の大幅な成長が予測されています。

地域の考察

北米市場は、進行中の疾患の発生件数の増加や、Illumina, Inc.（米国）、Gilead Sciences, Inc.（米国）、Celleron Therapeutics（米国）、LISEN lmprinting Diagnostics（米国）、Salarius Drugs, Inc.（米国）を含むダイナミックな大手企業のプレゼンスにより、2022年に最大の市場シェアを占めました。

欧州市場は、遺伝性疾患の優位性の高まりと、遺伝性疾患を検出するエピジェネティクス検査の普及により、第2位の市場シェアを占めています。

アジア太平洋市場は、神経疾患の発生の増加と医薬品開発に向けた組織的な活動の拡大により、健全な市場成長を記録すると予測されています。中国、インド、南アジア、西太平洋近隣諸国を含む発展途上国では、老年人口の急速な増加により、アルツハイマー病の罹患率が高くなっています。

当レポートでは、世界のエピジェネティクス医薬品・診断技術市場について調査分析し、市場力学、地域とセグメントの分析、企業プロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場のイントロダクション

第3章 調査手法

第4章 市場力学

  • 概要
  • 促進要因
  • 抑制要因
  • 機会

第5章 市場要因の分析

  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響の分析
    • 市場に対する影響の分析
    • 地域に対する影響
    • 機会と脅威の分析

第6章 世界のエピジェネティクス医薬品・診断技術市場：医薬品タイプ別

  • 概要
  • DNAメチルトランスフェラーゼ（DNMT）阻害薬
    • アザシチジン
    • デシタビン
    • その他
  • ヒストン脱アセチル化酵素（HDAC）阻害薬
    • ボリノスタット
    • ロミデプシン
    • その他
  • ヒストンメチルトランスフェラーゼ（HMT）阻害薬
  • その他

第7章 世界のエピジェネティクス医薬品・診断技術市場：診断技術別

  • 概要
  • DNAメチル化
  • ヒストン修飾解析
  • その他

第8章 世界のエピジェネティクス医薬品・診断技術市場：用途別

  • 概要
  • 腫瘍
  • 神経
  • 自己免疫疾患
  • その他

第9章 世界のエピジェネティクス医薬品・診断技術市場：エンドユーザー別

  • 概要
  • 病院・診療所
  • 診断研究所
  • その他

第10章 世界のエピジェネティクス医薬品・診断技術市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他の欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • その他のアジア太平洋
  • その他の地域
    • 中東
    • アフリカ
    • ラテンアメリカ

第11章 企業情勢

  • 概要
  • 競合の分析
  • 市場シェア分析
  • 世界のエピジェネティクス医薬品・診断技術市場における主な成長戦略
  • 競合ベンチマーキング
  • 世界のエピジェネティクス医薬品・診断技術市場における開発数の主要企業
  • 主な発展と成長戦略
  • 主要企業の財務マトリクス

第12章 企業プロファイル

  • HOLOGIC, INC.
  • GILEAD SCIENCES, INC.
  • CELLERON THERAPEUTICS
  • ILLUMINA, INC.
  • ASTRAZENECA PLC
  • LISEN LMPRINTING DIAGNOSTICS
  • SALARIUS PHARMACEUTICALS, INC.
  • JUBILANT THERAPEUTICS
  • ORYZON GENOMICS
  • EPIAXIS THERAPEUTICS

第13章 付録

図表

LIST OF TABLES

  • TABLE 1 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, SYNOPSIS, 2019-2032
  • TABLE 2 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)
  • TABLE 3 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019-2032 (USD BILLION)
  • TABLE 4 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 5 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 6 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019-2032 (USD BILLION)
  • TABLE 7 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
  • TABLE 8 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019-2032 (USD BILLION)
  • TABLE 9 NORTH AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019-2032 (USD BILLION)
  • TABLE 10 NORTH AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 11 NORTH AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 12 NORTH AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019-2032 (USD BILLION)
  • TABLE 13 NORTH AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
  • TABLE 14 NORTH AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019-2032 (USD BILLION)
  • TABLE 15 US: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019-2032 (USD BILLION)
  • TABLE 16 US: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 17 US: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 18 US: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019-2032 (USD BILLION)
  • TABLE 19 US: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
  • TABLE 20 US: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019-2032 (USD BILLION)
  • TABLE 21 CANADA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019-2032 (USD BILLION)
  • TABLE 22 CANADA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 23 CANADA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 24 CANADA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019-2032 (USD BILLION)
  • TABLE 25 CANADA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
  • TABLE 26 CANADA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019-2032 (USD BILLION)
  • TABLE 1 EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019-2032 (USD BILLION)
  • TABLE 2 EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 3 EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 4 EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019-2032 (USD BILLION)
  • TABLE 5 EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
  • TABLE 6 EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019-2032 (USD BILLION)
  • TABLE 7 GERMANY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019-2032 (USD BILLION)
  • TABLE 8 GERMANY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 9 GERMANY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 10 GERMANY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019-2032 (USD BILLION)
  • TABLE 11 GERMANY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
  • TABLE 12 GERMANY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019-2032 (USD BILLION)
  • TABLE 13 FRANCE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019-2032 (USD BILLION)
  • TABLE 14 FRANCE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 15 FRANCE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 16 FRANCE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019-2032 (USD BILLION)
  • TABLE 17 FRANCE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
  • TABLE 18 FRANCE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019-2032 (USD BILLION)
  • TABLE 19 ITALY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019-2032 (USD BILLION)
  • TABLE 20 ITALY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 21 ITALY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 22 ITALY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019-2032 (USD BILLION)
  • TABLE 23 ITALY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
  • TABLE 24 ITALY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019-2032 (USD BILLION)
  • TABLE 25 SPAIN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019-2032 (USD BILLION)
  • TABLE 26 SPAIN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 27 SPAIN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 28 SPAIN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019-2032 (USD BILLION)
  • TABLE 29 SPAIN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
  • TABLE 30 SPAIN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019-2032 (USD BILLION)
  • TABLE 31 UK: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019-2032 (USD BILLION)
  • TABLE 32 UK: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 33 UK: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 34 UK: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019-2032 (USD BILLION)
  • TABLE 35 UK: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
  • TABLE 36 UK: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019-2032 (USD BILLION)
  • TABLE 37 REST OF EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019-2032 (USD BILLION)
  • TABLE 38 REST OF EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 39 REST OF EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 40 REST OF EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019-2032 (USD BILLION)
  • TABLE 41 REST OF EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
  • TABLE 42 REST OF EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019-2032 (USD BILLION)
  • TABLE 43 ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019-2032 (USD BILLION)
  • TABLE 44 ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 45 ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 46 ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019-2032 (USD BILLION)
  • TABLE 47 ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
  • TABLE 48 ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019-2032 (USD BILLION)
  • TABLE 49 JAPAN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019-2032 (USD BILLION)
  • TABLE 50 JAPAN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 51 JAPAN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 52 JAPAN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019-2032 (USD BILLION)
  • TABLE 53 JAPAN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
  • TABLE 54 JAPAN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019-2032 (USD BILLION)
  • TABLE 55 CHINA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019-2032 (USD BILLION)
  • TABLE 56 CHINA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 57 CHINA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 58 CHINA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019-2032 (USD BILLION)
  • TABLE 59 CHINA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
  • TABLE 60 CHINA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019-2032 (USD BILLION)
  • TABLE 61 INDIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019-2032 (USD BILLION)
  • TABLE 62 INDIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 63 INDIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 64 INDIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019-2032 (USD BILLION)
  • TABLE 65 INDIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
  • TABLE 66 INDIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019-2032 (USD BILLION)
  • TABLE 67 AUSTRALIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019-2032 (USD BILLION)
  • TABLE 68 AUSTRALIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 69 AUSTRALIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 70 AUSTRALIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019-2032 (USD BILLION)
  • TABLE 71 AUSTRALIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
  • TABLE 72 AUSTRALIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019-2032 (USD BILLION)
  • TABLE 73 SOUTH KOREA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019-2032 (USD BILLION)
  • TABLE 74 SOUTH KOREA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 75 SOUTH KOREA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 76 SOUTH KOREA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019-2032 (USD BILLION)
  • TABLE 77 SOUTH KOREA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
  • TABLE 78 SOUTH KOREA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019-2032 (USD BILLION)
  • TABLE 79 REST OF ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019-2032 (USD BILLION)
  • TABLE 80 REST OF ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 81 REST OF ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 82 REST OF ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019-2032 (USD BILLION)
  • TABLE 83 REST OF ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
  • TABLE 84 REST OF ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019-2032 (USD BILLION)
  • TABLE 85 REST OF THE WORLD: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019-2032 (USD BILLION)
  • TABLE 86 REST OF THE WORLD: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 87 REST OF THE WORLD: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 88 REST OF THE WORLD: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019-2032 (USD BILLION)
  • TABLE 89 REST OF THE WORLD: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
  • TABLE 90 REST OF THE WORLD: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019-2032 (USD BILLION)
  • TABLE 91 MIDDLE EAST: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019-2032 (USD BILLION)
  • TABLE 92 MIDDLE EAST: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 93 MIDDLE EAST: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 94 MIDDLE EAST: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019-2032 (USD BILLION)
  • TABLE 95 MIDDLE EAST: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
  • TABLE 96 MIDDLE EAST: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019-2032 (USD BILLION)
  • TABLE 97 AFRICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019-2032 (USD BILLION)
  • TABLE 98 AFRICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 99 AFRICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 100 AFRICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019-2032 (USD BILLION)
  • TABLE 101 AFRICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
  • TABLE 102 AFRICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019-2032 (USD BILLION)
  • TABLE 103 LATIN AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019-2032 (USD BILLION)
  • TABLE 104 LATIN AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 105 LATIN AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 106 LATIN AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019-2032 (USD BILLION)
  • TABLE 107 LATIN AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
  • TABLE 108 LATIN AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019-2032 (USD BILLION)

LIST OF FIGURES

  • FIGURE 1 RESEARCH PROCESS
  • FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET
  • FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET
  • FIGURE 4 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, SHARE (%), BY DRUG TYPE, 2022
  • FIGURE 5 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, SHARE (%), BY DIAGNOSTIC TECHNOLOGIES, 2022
  • FIGURE 6 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, SHARE (%), BY APPLICATION, 2022
  • FIGURE 7 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, SHARE (%), BY END USER, 2022
  • FIGURE 8 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, SHARE (%), BY REGION, 2022
  • FIGURE 9 NORTH AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, SHARE (%), BY REGION, 2022
  • FIGURE 10 EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, SHARE (%), BY REGION, 2022
  • FIGURE 11 ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, SHARE (%), BY REGION, 2022
  • FIGURE 12 REST OF THE WORLD: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, SHARE (%), BY REGION, 2022
  • FIGURE 13 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET: COMPANY SHARE ANALYSIS (%), 2022
  • FIGURE 14 HOLOGIC, INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 15 HOLOGIC, INC.: SWOT ANALYSIS
  • FIGURE 16 GILEAD SCIENCES, INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 17 GILEAD SCIENCES, INC.: SWOT ANALYSIS
  • FIGURE 18 CELLERON THERAPEUTICS: SWOT ANALYSIS
  • FIGURE 19 ILLUMINA, INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 20 ILLUMINA, INC.: SWOT ANALYSIS
  • FIGURE 21 ASTRAZENECA PLC: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 22 ASTRAZENECA PLC: SWOT ANALYSIS
  • FIGURE 23 SALARIUS PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 24 JUBILANT THERAPEUTICS: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 25 ORYZON GENOMICS: FINANCIAL OVERVIEW SNAPSHOT
目次
Product Code: MRFR/HC/10457-CR

Market Overview

The Epigenetics Drugs and Diagnostic Technologies Market is anticipated to register a substantial CAGR of 21.90% during the review period.

The development of the market is driven by elements like the rising pervasiveness of persistent diseases like Focal Sensory system (CNS) diseases and oncology and the rising number of product dispatches and pipeline products.

The rising incidences of ongoing diseases of the focal sensory system across the globe are expanding the demand for epigenetic drugs and diagnostic technologies. Epigenetics significantly treat focal sensory system diseases, including Alzheimer's, Huntington's disease, schizophrenia, chemical imbalance, and bipolar disorder. Moreover, these drugs have low poisonousness and can be given in mix with different kinds of drugs for better treatment.

Additionally, epigenetics has shown extraordinary outcomes in treating malignant growth, and these drugs could switch off Deoxyribonucleic Acid (DNA). According to GLOBOCAN 2020, bosom disease accounted for the biggest offer, followed by lung, colorectum, prostate, stomach, and different malignant growths.

Market Segmentation

The market segments of epigenetics drugs and diagnostic technologies, based on drug type, into DNA methyltransferases (DNMTs) inhibitors, histone deacetylases (HDACs) inhibitors, histone methyltransferase (HMT) inhibitors, and others including bromodomain inhibitors, protein methyltransferase inhibitors, and histone acetyltransferases (HAT) inhibitors. The DNA methyltransferases (DNMTs) inhibitors segment is further segmented into azacitidine, decitabine, and others including zebularine, hydralazine, and procaine, and histone deacetylases (HDACs) inhibitors are further segmented into vorinostat, romidepsin, and others including belinostat, panobinostat, and trichostatin A.

The diagnostic technologies segment is classified into DNA methylation and histone modification analysis and others, including non-coding RNA analysis and epigenomic profiling.

Based on application, the market is separated into oncology, neurology, autoimmune diseases, and others. Based on end users the market is segmented into hospitals & and clinics, diagnostic centers, and others, including academic and research institutes and ambulatory surgical centers.

Regional Insights

North America epigenetics drugs and diagnostic technologies market held the biggest market share in 2022, due to the rising incidences of ongoing diseases and the presence of major and dynamic players including Illumina, Inc. (US), Gilead Sciences, Inc. (US), Celleron Therapeutics (US), LISEN lmprinting Diagnostics (US), and Salarius Drugs, Inc. (US).

Europe's epigenetics drugs and diagnostic technologies market accounted for the second-biggest market share due to the rising predominance of hereditary disorders and the send-off of epigenetic tests to detect hereditary disorders.

The Asia-Pacific epigenetics drugs and diagnostic technologies market is anticipated to register a healthy market growth owing to the developing incidence of neurological diseases and expanding coordinated efforts for the development of the drugs. According to the Alzheimer's Disease Global revealed in 2020, there are higher possibilities of Alzheimer's in developing nations including China, India, South Asia, and Western Pacific neighbors due to the quick development of the geriatric populace.

Major Players

Key Companies in the market of Epigenetics Drugs and Diagnostic Technologies are Hologic, Inc. (US), Gilead Sciences, Inc. (US), Celleron Therapeutics (US), Illumina, Inc. (US), AstraZeneca PLC (UK), LISEN lmprinting Diagnostics (US), Salarius Pharmaceuticals, Inc. (US), Jubilant Therapeutics (US), Oryzon Genomics (Spain), and Epiaxis Therapeutics (Australia).

TABLE OF CONTENTS

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

  • 2.1. DEFINITION
  • 2.2. SCOPE OF THE STUDY
    • 2.2.1. RESEARCH OBJECTIVE
    • 2.2.2. ASSUMPTIONS
    • 2.2.3. LIMITATIONS

3. RESEARCH METHODOLOGY

  • 3.1. OVERVIEW
  • 3.2. DATA MINING
  • 3.3. SECONDARY RESEARCH
  • 3.4. PRIMARY RESEARCH
    • 3.4.1. PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
    • 3.4.2. BREAKDOWN OF PRIMARY RESPONDENTS
  • 3.5. FORECASTING TECHNIQUE
  • 3.6. MARKET SIZE ESTIMATION
    • 3.6.1. BOTTOM-UP APPROACH
    • 3.6.2. TOP-DOWN APPROACH
  • 3.7. DATA TRIANGULATION
  • 3.8. VALIDATION

4. MARKET DYNAMICS

  • 4.1. OVERVIEW
  • 4.2. DRIVERS
  • 4.3. RESTRAINTS
  • 4.4. OPPORTUNITIES

5. MARKET FACTOR ANALYSIS

  • 5.1. VALUE CHAIN ANALYSIS
  • 5.2. PORTER'S FIVE FORCES ANALYSIS
    • 5.2.1. BARGAINING POWER OF SUPPLIERS
    • 5.2.2. BARGAINING POWER OF BUYERS
    • 5.2.3. THREAT OF NEW ENTRANTS
    • 5.2.4. THREAT OF SUBSTITUTES
    • 5.2.5. INTENSITY OF RIVALRY
  • 5.3. COVID-19 IMPACT ANALYSIS
    • 5.3.1. MARKET IMPACT ANALYSIS
    • 5.3.2. REGIONAL IMPACT
    • 5.3.3. OPPORTUNITY AND THREAT ANALYSIS

6. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE

  • 6.1. OVERVIEW
  • 6.2. DNA METHYLTRANSFERASES (DNMTS) INHIBITORS
    • 6.2.1. AZACITIDINE
    • 6.2.2. DECITABINE
    • 6.2.3. OTHERS
  • 6.3. HISTONE DEACETYLASES (HDACS) INHIBITORS
    • 6.3.1. VORINOSTAT
    • 6.3.2. ROMIDEPSIN
    • 6.3.3. OTHERS
  • 6.4. HISTONE METHYLTRANSFERASE (HMT) INHIBITORS
  • 6.5. OTHERS

7. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES

  • 7.1. OVERVIEW
  • 7.2. DNA METHYLATION
  • 7.3. HISTONE MODIFICATION ANALYSIS
  • 7.4. OTHERS

8. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION

  • 8.1. OVERVIEW
  • 8.2. ONCOLOGY
  • 8.3. NEUROLOGY
  • 8.4. AUTOIMMUNE DISEASES
  • 8.5. OTHERS

9. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER

  • 9.1. OVERVIEW
  • 9.2. HOSPITALS & CLINICS
  • 9.3. DIAGNOSTIC LABORATORIES
  • 9.4. OTHERS

10. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY REGION

  • 10.1. OVERVIEW
  • 10.1. NORTH AMERICA
    • 10.1.1. US
    • 10.1.2. CANADA
  • 10.2. EUROPE
    • 10.2.1. GERMANY
    • 10.2.2. FRANCE
    • 10.2.3. UK
    • 10.2.4. ITALY
    • 10.2.5. SPAIN
    • 10.2.6. REST OF EUROPE
  • 10.3. ASIA-PACIFIC
    • 10.3.1. CHINA
    • 10.3.2. INDIA
    • 10.3.3. JAPAN
    • 10.3.4. SOUTH KOREA
    • 10.3.5. AUSTRALIA
    • 10.3.6. REST OF ASIA-PACIFIC
  • 10.4. REST OF THE WORLD
    • 10.4.1. MIDDLE EAST
    • 10.4.2. AFRICA
    • 10.4.3. LATIN AMERICA

11. COMPANY LANDSCAPE

  • 11.1. OVERVIEW
  • 11.2. COMPETITIVE ANALYSIS
  • 11.3. MARKET SHARE ANALYSIS
  • 11.4. MAJOR GROWTH STRATEGY IN THE GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET
  • 11.5. COMPETITIVE BENCHMARKING
  • 11.6. LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET
  • 11.7. KEY DEVELOPMENTS AND GROWTH STRATEGIES
    • 11.7.1. NEW PRODUCT LAUNCH
    • 11.7.2. MERGER & ACQUISITIONS
    • 11.7.3. JOINT VENTURES
  • 11.8. MAJOR PLAYERS FINANCIAL MATRIX
    • 11.8.1. SALES & OPERATING INCOME, 2022
    • 11.8.2. MAJOR PLAYERS R&D EXPENDITURE. 2022

12. COMPANY PROFILES

  • 12.1. HOLOGIC, INC.
    • 12.1.1. COMPANY OVERVIEW
    • 12.1.2. FINANCIAL OVERVIEW
    • 12.1.3. PRODUCTS OFFERED
    • 12.1.4. KEY DEVELOPMENTS
    • 12.1.5. SWOT ANALYSIS
    • 12.1.6. KEY STRATEGIES
  • 12.2. GILEAD SCIENCES, INC.
    • 12.2.1. COMPANY OVERVIEW
    • 12.2.2. FINANCIAL OVERVIEW
    • 12.2.3. PRODUCTS OFFERED
    • 12.2.4. KEY DEVELOPMENTS
    • 12.2.5. SWOT ANALYSIS
    • 12.2.6. KEY STRATEGIES
  • 12.3. CELLERON THERAPEUTICS
    • 12.3.1. COMPANY OVERVIEW
    • 12.3.2. FINANCIAL OVERVIEW
    • 12.3.3. PRODUCTS OFFERED
    • 12.3.4. KEY DEVELOPMENTS
    • 12.3.5. SWOT ANALYSIS
    • 12.3.6. KEY STRATEGIES
  • 12.4. ILLUMINA, INC.
    • 12.4.1. COMPANY OVERVIEW
    • 12.4.2. FINANCIAL OVERVIEW
    • 12.4.3. PRODUCTS OFFERED
    • 12.4.4. KEY DEVELOPMENTS
    • 12.4.5. SWOT ANALYSIS
    • 12.4.6. KEY STRATEGIES
  • 12.5. ASTRAZENECA PLC
    • 12.5.1. COMPANY OVERVIEW
    • 12.5.2. FINANCIAL OVERVIEW
    • 12.5.3. PRODUCTS OFFERED
    • 12.5.4. KEY DEVELOPMENTS
    • 12.5.5. SWOT ANALYSIS
    • 12.5.6. KEY STRATEGIES
  • 12.6. LISEN LMPRINTING DIAGNOSTICS
    • 12.6.1. COMPANY OVERVIEW
    • 12.6.2. FINANCIAL OVERVIEW
    • 12.6.3. PRODUCTS OFFERED
    • 12.6.4. KEY DEVELOPMENTS
    • 12.6.5. SWOT ANALYSIS
    • 12.6.6. KEY STRATEGIES
  • 12.7. SALARIUS PHARMACEUTICALS, INC.
    • 12.7.1. COMPANY OVERVIEW
    • 12.7.2. FINANCIAL OVERVIEW
    • 12.7.3. PRODUCTS OFFERED
    • 12.7.4. KEY DEVELOPMENTS
    • 12.7.5. SWOT ANALYSIS
    • 12.7.6. KEY STRATEGIES
  • 12.8. JUBILANT THERAPEUTICS
    • 12.8.1. COMPANY OVERVIEW
    • 12.8.2. FINANCIAL OVERVIEW
    • 12.8.3. PRODUCTS OFFERED
    • 12.8.4. KEY DEVELOPMENTS
    • 12.8.5. SWOT ANALYSIS
    • 12.8.6. KEY STRATEGIES
  • 12.9. ORYZON GENOMICS
    • 12.9.1. COMPANY OVERVIEW
    • 12.9.2. FINANCIAL OVERVIEW
    • 12.9.3. PRODUCTS OFFERED
    • 12.9.4. KEY DEVELOPMENTS
    • 12.9.5. SWOT ANALYSIS
    • 12.9.6. KEY STRATEGIES
  • 12.10. EPIAXIS THERAPEUTICS
    • 12.10.1. COMPANY OVERVIEW
    • 12.10.2. FINANCIAL OVERVIEW
    • 12.10.3. PRODUCTS OFFERED
    • 12.10.4. KEY DEVELOPMENTS
    • 12.10.5. SWOT ANALYSIS
    • 12.10.6. KEY STRATEGIES

13. APPENDIX

  • 13.1. REFERENCES
  • 13.2. RELATED REPORTS